SCHEDULE: Adage Capital Boosts Amylyx Stake to 9.87%

Adage Capital Management and its principals have reported a 9.87% beneficial ownership stake in Amylyx Pharmaceuticals, holding 8.8 million shares.

Summary

• Adage Capital Management, L.P., Robert Atchinson, and Phillip Gross collectively reported beneficial ownership of 8,800,000 shares of Amylyx Pharmaceuticals, Inc. Common Stock.
• This ownership represents 9.87% of the company's outstanding Common Stock.
• The percentage is calculated based on 89,141,087 shares of Common Stock outstanding as of April 28, 2025, as reported in Amylyx's Quarterly Report on Form 10-Q filed on May 8, 2025.
• The Reporting Persons hold shared voting power and shared dispositive power over all 8,800,000 shares.
• The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing the control of Amylyx Pharmaceuticals, Inc.

Sentiment

Score: 5

Explanation: The filing is a factual disclosure of beneficial ownership and does not inherently convey positive or negative sentiment regarding the company's performance or outlook. It simply reports a significant passive investment.

Positives

• A significant institutional investor, Adage Capital Management, L.P., has disclosed a substantial 9.87% stake in Amylyx Pharmaceuticals, indicating confidence in the company's long-term prospects as a passive investment.

Future Outlook

This filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance from the reporting entity regarding Amylyx Pharmaceuticals, Inc.'s future performance or strategic direction.

Management Comments

• The securities were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under Rule 14a-11.

Industry Context

The disclosure of a significant passive stake by a major institutional investor like Adage Capital Management in Amylyx Pharmaceuticals highlights continued institutional interest in the biotechnology and pharmaceutical sectors. Such investments often reflect a belief in the long-term value proposition of companies developing novel therapies.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional holder may be viewed positively, potentially signaling confidence in the company and its prospects, which could influence market perception and trading activity.

Key Dates

Keywords

Amylyx Pharmaceuticals, Adage Capital Management, Institutional Ownership, Beneficial Ownership, Common Stock, Pharmaceuticals, Investment Management, Healthcare